Jon Kostas

"60 Minutes" segment with Anderson Cooper on psilocybin medical treatment for mental & behavioral health.

The FDA is on the HUNT for promising therapies.

.@DrMakaryFDA: What @POTUS did is we sent a strong message that this administration is going to prioritize treating mental illness in this country and look at alternative new approaches. We’ve lost more veterans to suicide since the Iraq War than the troops we lost during the Iraq War.

Following President Trump’s directive to accelerate medical treatments for serious mental illnesses, FDA announced major steps to support the development of serotonin-2A agonists & related products—a class of medications historically referred to as "psychedelic" drugs. ✅ National priority vouchers for psilocybin (for treatment-resistant depression and major depressive disorder) ✅ National priority voucher for methylone (for post-traumatic stress disorder) ✅ First-ever noribogaine study authorized for alcohol use disorder ✅ Advancing guidance for sponsors developing these products Learn more: fda.gov/news-events/pr…

We are proud to have our statement featured by the @WhiteHouse. We stand ready to work with the administration to deliver regulated, science-based hope to our veterans. @POTUS #Psychedelics #ExecutiveOrder

We are proud to be featured in today's @WhiteHouse announcement on President Trump's landmark #ExecutiveOrder. Our mission to accelerate safe, regulated, and science-based #psychedelic medicines is now a national priority. whitehouse.gov/releases/2026/… @POTUS @RapidResponse47

Helus Pharma was honoured to be among the organizations quoted in today’s White House release accompanying the Executive Order advancing breakthrough mental health treatments for the benefit of patients in need. Read more: whitehouse.gov/releases/2026/…

President Trump’s Landmark Order Advances Breakthrough Mental Health Treatments — Delivering New Hope to Veterans whitehouse.gov/releases/2026/…

Today’s Executive Order directing federal agencies to accelerate research and clarify regulatory pathways for psychedelic and related mental health therapies reflects growing recognition of the urgent need for new treatment options for serious mental health conditions. Increased federal attention to this area highlights both the scale of unmet need and the importance of advancing rigorously studied therapies through well-designed clinical trials and clear regulatory expectations. At Helus Pharma, we believe meaningful progress depends on disciplined research, thoughtful clinical development, and the FDA’s established, science-based approval pathway. Collaboration across elected leaders, regulators, clinicians, and industry will be essential to advancing innovation responsibly and ensuring patients can benefit from safe, effective, and scalable new therapeutic options.

A landmark moment for mental health and psychedelics. Today's Executive Order potentially accelerates much needed therapies to patients, including our portfolio of next-generation, rapid-acting psychedelics. whitehouse.gov/presidential-a… $ATAI #MentalHealth #Biotech #CreatingBreakthroughsinMentalHeath

A breakthrough approach to mental health. 🇺🇸

The @WhiteHouse Executive Order to accelerate research into psychedelic treatments targeting serious mental illness is a landmark moment for our country, our industry and, most importantly, patients. We applaud this critical step and are ready to meet this moment, keeping scientific rigor as our north star. Read more here: bit.ly/4tX665M #DefiniumTherapeutics #MentalHealthInnovation

The fastest way to deliver hope is through science-based pathways. Thank you @StatNews for featuring our statement on today’s Executive Order. Read more on why this is a game-changer for veterans and patients across America: 👇

Trump directed the federal government to rush access to psychedelic treatments and reevaluate their status as controlled substances. trib.al/Ywg4xEk

Today’s Executive Order is a major step toward delivering safe, FDA-regulated psychedelic therapies to those who need them most. Grateful for the leadership of @POTUS and the Administration. Read our full statement below. 👇

A historic day! This #ExecutiveOrder is a vital step toward delivering breakthrough therapies through the proper #FDA approval pathway. We applaud the administration for prioritizing the health of our veterans and all Americans in need of solutions.

How Trump is pushing psychedelics reform through the health agencies | STAT statnews.com/2026/04/18/psy…

Thank you, President Trump. We need an all-of-the-above strategy when it comes to tackling mental health, and your EO opens up new possibilities for America’s Veterans.

The Association for Prescription Psychedelics recently met with VA Secretary Doug Collins for a forward-focused conversation on innovative, science-driven approaches to improving mental health care for veterans.

Had a great time at Association for Prescription Psychedelics Congressional reception last night. @PsychedelicsRX is advancing federal funding for psychedelic research and patient access post-FDA approval. Peter Hendricks & Fred Barrett will brief Congressional PATH Caucus today.

Research and clinical studies show that prescription psychedelic medicines have the potential to help patients diagnosed with a wide range of health conditions. Let’s commit to the medical model and help expand access to these innovative treatments. bit.ly/3PmMdCW